Skip to content
Monte Rosa Therapeutics, Inc· @MonteRosaTx · X·· 2026-04-20Score60
Body · original

We’re presenting preclinical data at #AACR26 on the potential of our CCNE1-directed molecular glue degrader to treat CCNE1-amplified solid tumors, suggesting a potential new approach to a historically undruggable target.

Learn more:
https://
bit.ly/48M39g3

Heat 5 · 4 likes · 0 replies · 1 repost

Source: Monte Rosa Therapeutics, Inc · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org